![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » DOMINANT DRUGS FROM SANOFI-AVENTIS, GLAXOSMITHKLINE, AND PFIZER WILL LOSE SIGNIFICANT SHARE TO NOVEL AGENTS IN THE VENOUS THROMBOEMBOLISM TREATMENT AND PROPHYLAXIS MARKETS
DOMINANT DRUGS FROM SANOFI-AVENTIS, GLAXOSMITHKLINE, AND PFIZER WILL LOSE SIGNIFICANT SHARE TO NOVEL AGENTS IN THE VENOUS THROMBOEMBOLISM TREATMENT AND PROPHYLAXIS MARKETS
Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the increasing use of low-molecular-weight heparins, including drugs from Sanofi-Aventis, GlaxoSmithKline, and Pfizer, the market dominance of these therapies in the treatment and prophylaxis of venous thromboembolism will be significantly eroded by novel agents over the 2005-2015 forecast period.
PR Newswire (http://sev.prnewswire.com/medical-pharmaceuticals/20060926/NETU00926092006-1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct